<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611480</url>
  </required_header>
  <id_info>
    <org_study_id>LIMTOP-I</org_study_id>
    <nct_id>NCT01611480</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moberg Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moberg Pharma AB</source>
  <brief_summary>
    <textblock>
      The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a&#xD;
      study involving 96 patients with actinic keratosis on the head or face.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Actinic Keratosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod (topical use)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent form (ICF) signed and dated by the patient prior to any&#xD;
             study-related activity&#xD;
&#xD;
          2. Male or female patients aged 18 or older&#xD;
&#xD;
          3. Have a total of 5-20 clinically confirmed, palpable or visible (grade I or II&#xD;
             according to modified Olsen score) nonhyperkeratotic, nonhypertrophic AK lesions&#xD;
             located within a contiguous 25 - 100 cm² area on the balding scalp or face&#xD;
&#xD;
          4. Any skin type or race, providing the skin pigmentation will allow discernment of&#xD;
             erythema&#xD;
&#xD;
          5. Willingness to actively participate in the study and to comply with the study&#xD;
             procedures as defined in the study protocol&#xD;
&#xD;
          6. High probability of a good compliance and orderly completion of the study&#xD;
&#xD;
          7. Negative urine pregnancy test (in female subjects with childbearing potential)&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of clinically significant, unstable cardiovascular or immunosuppressive,&#xD;
             hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or&#xD;
             gastrointestinal abnormalities or disease&#xD;
&#xD;
          2. Diagnosed autoimmune diseases and anaemia&#xD;
&#xD;
          3. Any dermatological disease and or condition in the treatment or surrounding area that&#xD;
             may be exacerbated by treatment with imiquimod or cause difficulty with examination&#xD;
             (e.g. rosacea, psoriasis, atopic dermatitis, eczema)&#xD;
&#xD;
          4. Any significant findings (e.g. tattoos) in the potential application site area that&#xD;
             may impair examination of treatment or surrounding area&#xD;
&#xD;
          5. Confirmed squamous cell or basal cell carcinoma anywhere on the head in the past 3&#xD;
             months&#xD;
&#xD;
          6. Share a household where there is a person participating in a concurrent clinical study&#xD;
             of imiquimod or being treated with imiquimod 5% topical cream&#xD;
&#xD;
          7. Active chemical dependency or alcoholism, as assessed by investigator&#xD;
&#xD;
          8. Patients unwilling to stay out of the sun or wear protective clothing or to take&#xD;
             appropriate measures to cover the treatment area during the study&#xD;
&#xD;
          9. Previous treatments with imiquimod for AK in the predetermined treatment area within&#xD;
             the past 3 months&#xD;
&#xD;
         10. Treatment with COX-2 inhibitors 14 days prior to randomization&#xD;
&#xD;
         11. Currently using or have used on the treatment area over-the-counter retinol products,&#xD;
             corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic&#xD;
             keratosis treatments 28 days prior to randomization&#xD;
&#xD;
         12. Subjects who experienced an unsuccessful outcome from previous imiquimod therapy.&#xD;
&#xD;
         13. Known allergy or sensitivity to imiquimod or any of the excipients (butyl lactate,&#xD;
             isopropyl myristate, propylene glycol, butylated hydroxy anisole) in the IMP&#xD;
&#xD;
         14. Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women&#xD;
             who:&#xD;
&#xD;
               -  are pregnant or nursing,&#xD;
&#xD;
               -  are not surgically sterile,&#xD;
&#xD;
               -  are of child bearing potential and not practicing an acceptable method of birth&#xD;
                  control, or does not plan to continue practicing an acceptable method of birth&#xD;
                  control throughout the trial (acceptable methods include intrauterine devices&#xD;
                  (IUD), oral, implantable or injectable contraceptives, diaphragm or cervical cap&#xD;
                  with intravaginal spermicide, condom with intravaginal spermicide or vasectomised&#xD;
                  partner)&#xD;
&#xD;
         15. Participation in another clinical trial with an investigational drug or device during&#xD;
             the previous 4 weeks before Baseline&#xD;
&#xD;
         16. Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser&#xD;
             abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study&#xD;
             entry.&#xD;
&#xD;
         17. Currently using or have used systemic steroids 2 months prior to study except inhaled&#xD;
             corticosteroids (&lt;1200 microgram/day for beclomethasone, or &lt;600 microgram/day for&#xD;
             fluticasone)&#xD;
&#xD;
         18. Known infectious diseases (e.g. HIV, hepatitis)&#xD;
&#xD;
         19. Psychiatric condition that might limit the participation in the study and/or that lead&#xD;
             to the assumption that the ability to completely understand the consequences of&#xD;
             consent is missing&#xD;
&#xD;
         20. The Patient is institutionalized by virtue of an order issued either by the judicial&#xD;
             or the administrative authorities&#xD;
&#xD;
         21. Employee of the study site or of the Sponsor's company&#xD;
&#xD;
         22. Any disease or circumstances on account of which the subject should not participate in&#xD;
             the study in the opinion of the investigator -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>5 Locations</name>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

